A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors

Increasing knowledge of intertumor heterogeneity, intratumor heterogeneity, and cancer evolution has improved the understanding of anticancer treatment resistance. A better characterization of cancer evolution and subsequent use of this knowledge for personalized treatment would increase the chance to overcome cancer treatment resistance. Model‐based approaches may help achieve this goal. In this review, we comprehensively summarized mathematical models of tumor dynamics for solid tumors and of drug resistance evolution. Models displayed by ordinary differential equations, algebraic equations, and partial differential equations for characterizing tumor burden dynamics are introduced and discussed. As for tumor resistance evolution, stochastic and deterministic models are introduced and discussed. The results may facilitate a novel model‐based analysis on anticancer treatment response and the occurrence of resistance, which incorporates both tumor dynamics and resistance evolution. The opportunities of a model‐based approach as discussed in this review can be of great benefit for future optimizing and personalizing anticancer treatment.

[1]  Yongzhao Shao,et al.  Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates , 2016, Scientific Reports.

[2]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[3]  Kazuyuki Aihara,et al.  Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.

[4]  J. Murray,et al.  Glioblastoma brain tumours: estimating the time from brain tumour initiation and resolution of a patient survival anomaly after similar treatment protocols , 2012, Journal of biological dynamics.

[5]  F. Ghalichi,et al.  Image based modeling of tumor growth , 2016, Australasian Physical & Engineering Sciences in Medicine.

[6]  Thomas E Yankeelov,et al.  Clinically Relevant Modeling of Tumor Growth and Treatment Response , 2013, Science Translational Medicine.

[7]  J G Coen van Hasselt,et al.  Towards integrative systems pharmacology models in oncology drug development. , 2015, Drug discovery today. Technologies.

[8]  K. Swanson,et al.  A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle , 2007, British Journal of Cancer.

[9]  D. Levy,et al.  An elementary approach to modeling drug resistance in cancer. , 2010, Mathematical biosciences and engineering : MBE.

[10]  R Bruno,et al.  Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A , 2016, CPT: pharmacometrics & systems pharmacology.

[11]  Hervé Delingette,et al.  Personalized Radiotherapy Planning Based on a Computational Tumor Growth Model , 2017, IEEE Transactions on Medical Imaging.

[12]  B. Ribba,et al.  Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2 , 2016, Cancer Chemotherapy and Pharmacology.

[13]  Gargi Chakraborty,et al.  Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.

[14]  Lena E Friberg,et al.  Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response , 2013, British journal of clinical pharmacology.

[15]  I. Trocóniz,et al.  Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. , 2016, The oncologist.

[16]  Valder Steffen,et al.  Determination of an optimal control strategy for drug administration in tumor treatment using multi-objective optimization differential evolution , 2016, Comput. Methods Programs Biomed..

[17]  Ezio Venturino,et al.  A two-clones tumor model: Spontaneous growth and response to treatment. , 2016, Mathematical biosciences.

[18]  Trevor A Graham,et al.  New paradigms in clonal evolution: punctuated equilibrium in cancer , 2016, The Journal of pathology.

[19]  L E Friberg,et al.  A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis , 2014, CPT: pharmacometrics & systems pharmacology.

[20]  Yuri Kogan,et al.  Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models , 2010, PloS one.

[21]  Johan Hartman,et al.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing , 2018, Cell.

[22]  Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation , 2016, BMC Cancer.

[23]  Fang-Fang Hao,et al.  A nonlinear competitive model of the prostate tumor growth under intermittent androgen suppression. , 2016, Journal of theoretical biology.

[24]  Anubha Gupta,et al.  Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes , 2014, Journal of clinical pharmacology.

[25]  R. F. Allen A Commentary , 1966 .

[26]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[27]  Nicolas André,et al.  Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.

[28]  D. Wodarz,et al.  Mathematical Modeling of Cyclic Cancer Treatments , 2014 .

[29]  K. Badani,et al.  Heterogeneity in renal cell carcinoma. , 2017, Urologic oncology.

[30]  Pietro Cerveri,et al.  Adaptive Mathematical Model of Tumor Response to Radiotherapy Based on CBCT Data , 2016, IEEE Journal of Biomedical and Health Informatics.

[31]  Thomas E Yankeelov,et al.  Integration of diffusion‐weighted MRI data and a simple mathematical model to predict breast tumor cellularity during neoadjuvant chemotherapy , 2011, Magnetic resonance in medicine.

[32]  A. Murugan,et al.  Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. , 2007, Mathematical biosciences.

[33]  Vishal Patel,et al.  Image-driven modeling of the proliferation and necrosis of glioblastoma multiforme , 2017, Theoretical Biology and Medical Modelling.

[34]  Zvia Agur,et al.  Personalizing oncology treatments by predicting drug efficacy, side‐effects, and improved therapy: mathematics, statistics, and their integration , 2014, Wiley interdisciplinary reviews. Systems biology and medicine.

[35]  Gouhei Tanaka,et al.  A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer , 2008, J. Nonlinear Sci..

[36]  Huimin Wang,et al.  Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients , 2017, Oncotarget.

[37]  Martin A Nowak,et al.  Dynamics of targeted cancer therapy. , 2012, Trends in molecular medicine.

[38]  Dominik Wodarz,et al.  Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) , 2014, Proceedings of the National Academy of Sciences.

[39]  Camille Stephan-Otto Attolini,et al.  Evolutionary Theory of Cancer , 2009, Annals of the New York Academy of Sciences.

[40]  Thomas E Yankeelov,et al.  A mechanically coupled reaction–diffusion model for predicting the response of breast tumors to neoadjuvant chemotherapy , 2013, Physics in medicine and biology.

[41]  J. Gerring A case study , 2011, Technology and Society.

[42]  Leslie Roberts,et al.  A Proof of Principle , 2007, Science.

[43]  M. Gottesman,et al.  The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[44]  T. Fojo,et al.  Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. , 2008, The oncologist.

[45]  P Forouhi,et al.  Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response , 2000, British Journal of Cancer.

[46]  T. Fojo,et al.  Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. , 2008, The oncologist.

[47]  Franziska Michor,et al.  Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. , 2017, Cancer research.

[48]  M. Gottesman,et al.  The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance , 2013 .

[49]  Bin Hu,et al.  Mathematical modeling and computational prediction of cancer drug resistance , 2017, Briefings Bioinform..

[50]  Fei Li,et al.  Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients , 2015, PloS one.

[51]  Nenad Sarapa,et al.  Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  D. Lauffenburger,et al.  Modeling Tumor Clonal Evolution for Drug Combinations Design. , 2016, Trends in cancer.

[53]  T. Fojo,et al.  Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy , 2010, Clinical Cancer Research.

[54]  D. Juric,et al.  Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. , 2014, British journal of clinical pharmacology.

[55]  Udo Schumacher,et al.  Simulation of metastatic progression using a computer model including chemotherapy and radiation therapy , 2015, J. Biomed. Informatics.

[56]  Vangelis Sakkalis,et al.  Evaluation framework for the multilevel macroscopic models of solid tumor growth in the glioma case , 2010, 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.

[57]  Martin A Nowak,et al.  Evolution of Resistance During Clonal Expansion , 2006, Genetics.

[58]  Luc Taillandier,et al.  Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm , 2008, Neurosurgical Review.

[59]  Chen-Hsiang Yeang,et al.  Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.

[60]  R. Bruno,et al.  Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients With Non–Small Cell Lung Cancer Based on MONET1 Study Results , 2014, Clinical pharmacology and therapeutics.

[61]  N. Enas,et al.  Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer. , 2016, British journal of clinical pharmacology.

[62]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[63]  N. Dubin Mathematical Model , 2022 .

[64]  Jan Fagerberg,et al.  Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Panetta,et al.  Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma , 2008, Clinical Cancer Research.

[66]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Ami Radunskaya,et al.  The dynamics of an optimally controlled tumor model: A case study , 2003 .

[68]  Albert Lai,et al.  Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.

[69]  David Basanta,et al.  Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2011, Molecular pharmaceutics.

[70]  B P Booth,et al.  Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.

[71]  F. Michor,et al.  Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.

[72]  N. Komarova,et al.  Stochastic modeling of drug resistance in cancer. , 2006, Journal of theoretical biology.

[73]  Franziska Michor,et al.  Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..

[74]  Kazuyuki Aihara,et al.  Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer. , 2014, Methods.

[75]  A. Samson,et al.  Analysis of temozolomide resistance in low‐grade gliomas using a mechanistic mathematical model , 2017, Fundamental & clinical pharmacology.

[76]  Gouhei Tanaka,et al.  Mathematical modelling of prostate cancer growth and its application to hormone therapy , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[77]  E. Holmgren,et al.  Endpoints for agents that slow tumor growth. , 2007, Contemporary clinical trials.

[78]  U. Ledzewicz,et al.  On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach. , 2016, Mathematical biosciences and engineering : MBE.

[79]  Urszula Ledzewicz,et al.  Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment. , 2010, Mathematical medicine and biology : a journal of the IMA.

[80]  W. Pope,et al.  Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma , 2016, Cancer science.

[81]  Joseph D Butner,et al.  Simulating cancer growth with multiscale agent-based modeling. , 2015, Seminars in cancer biology.

[82]  Martin A Nowak,et al.  Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers , 2014, Proceedings of the National Academy of Sciences.

[83]  Peter L. Bonate,et al.  Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma , 2013, Cancer Chemotherapy and Pharmacology.

[84]  Thomas E Yankeelov,et al.  Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model. , 2015, Cancer research.

[85]  F. Markowetz,et al.  Cancer Evolution: Mathematical Models and Computational Inference , 2014, Systematic biology.

[86]  S. Halachmi,et al.  Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model. , 2016, Mathematical medicine and biology : a journal of the IMA.

[87]  B. Houk,et al.  Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients , 2015, Cancer Chemotherapy and Pharmacology.

[88]  Kristin R. Swanson,et al.  The Evolution of Mathematical Modeling of Glioma Proliferation and Invasion , 2007, Journal of neuropathology and experimental neurology.

[89]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[90]  Ali Najafi,et al.  Seminars in Cancer Biology , 2014 .

[91]  M. Karlsson,et al.  PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST , 2013, CPT: pharmacometrics & systems pharmacology.

[92]  D. Ouellet,et al.  Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma , 2015, CPT: pharmacometrics & systems pharmacology.

[93]  José Pinheiro,et al.  Model‐based clinical drug development in the past, present and future: a commentary , 2015, British journal of clinical pharmacology.

[94]  Carl T. Bergstrom,et al.  Dynamics of preventive vs post-diagnostic cancer control using low-impact measures , 2015, eLife.

[95]  Jean Clairambault,et al.  Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation. , 2016, Biochimica et biophysica acta.

[96]  Yang Kuang,et al.  Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. , 2014, Cancer research.

[97]  F. Michor,et al.  Evolution of resistance to anti-cancer therapy during general dosing schedules. , 2010, Journal of theoretical biology.

[98]  Johan Pallud,et al.  A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy , 2012, Clinical Cancer Research.

[99]  D. Wodarz,et al.  Effect of cellular quiescence on the success of targeted CML therapy , 2022 .

[100]  Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial , 2012, BMC Cancer.

[101]  Shea N Gardner,et al.  Modeling multi-drug chemotherapy: tailoring treatment to individuals. , 2002, Journal of theoretical biology.

[102]  Antoine Ferreira,et al.  Modeling of Optimal Targeted Therapies Using Drug-Loaded Magnetic Nanoparticles for Liver Cancer , 2016, IEEE Transactions on NanoBioscience.

[103]  Natalia L Komarova,et al.  The Worst Drug Rule Revisited: Mathematical Modeling of Cyclic Cancer Treatments , 2011, Bulletin of mathematical biology.

[104]  M. Maitland,et al.  Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling , 2016, Clinical and translational science.